Federal Legislation Re: Scheduling of Xylazine

On December 12, 2023 the House passed the Support for Patients and Communities Reauthorization Act (SUPPORT Act), which contains key components of the AVMA-endorsed Combating Illicit Xylazine Act. The language within the SUPPORT Act would schedule xylazine as a Schedule III drug while exempting from scheduling the FDA-approved animal drug, which means, if enacted, veterinarians […]